The resolution addresses the significant public health issue of obesity in Alabama, highlighting its complex causes and the associated risks of diseases such as heart disease and diabetes. It notes that obesity incurs substantial medical costs, with the Centers for Disease Control reporting nearly $173 billion in annual expenditures nationwide, and estimates that Alabama's economy has suffered a $7.2 billion impact due to obesity. The prevalence of obesity in Alabama is concerning, with 38.9% of adults and 15.6% of children enrolled in the Women, Infants, and Children program affected. The resolution also references new drug pricing models from the Centers for Medicare and Medicaid Services that could influence Medicaid programs and the potential qualification of approximately 110,000 individuals for GLP-1 medications for weight management.

In response to these challenges, the resolution encourages the Alabama Medicaid Agency to take several actions. These include determining potential savings from covering GLP-1 medications, evaluating the overall costs of such coverage in light of new drug pricing models, engaging with healthcare providers and stakeholders to improve health outcomes and cost savings, and reporting findings to the Legislature before the 2027 Legislative Session. The resolution aims to explore the benefits of GLP-1 medications for weight management and their implications for the state's healthcare system and budget.